India Glycols Posts Rs. 358.18 Crore Revenue and Rs. 39.34 Crore EBITDA in Q2 FY27 Post-Demerger
Standalone results reflect continuing operations following demerger of Spirits & Biofuel and Biopharma units effective April 1, 2026
India Glycols Limited announced its unaudited standalone financial results for Q2 FY27 after the demerger of its Spirits, Biofuel, and Biopharma undertakings. The company reported revenue of Rs. 358.18 crore and EBITDA of Rs. 39.34 crore reflecting continuing operations focused on bio-based specialty materials and sustainable chemicals.
India Glycols Limited
General / Other
India Glycols Limited announced its standalone unaudited financial results for the quarter ended September 30, 2026, reporting revenue of Rs. 358.18 crore and EBITDA of Rs. 39.34 crore after demerging its Spirits & Biofuel and Biopharma undertakings into separately listed entities.
The second quarter (Q2 FY27) results reflect continuing operations focused on bio-based specialty materials, sustainable and performance chemicals, and gases. The Spirits & Biofuel Undertaking and the Biopharma Undertaking were demerged into IGL Spirits Limited and Ennature Bio Pharma Limited, respectively, effective from April 1, 2026, impacting comparability with prior periods.
For Q2 FY27, revenue stood at Rs. 358.18 crore, with an EBITDA of Rs. 39.34 crore and Profit After Tax (PAT) of Rs. 11.24 crore. Quarterly earnings per share (EPS) were Rs. 1.68.
Comparatively, Q2 FY26 figures included the demerged units, showing revenues of Rs. 2,410.71 crore and EBITDA of Rs. 160.25 crore. The financial results are not comparable due to the structural changes from the demerger.
For the half year ended September 30, 2026 (H1 FY27), revenue from operations was Rs. 712.82 crore, EBITDA was Rs. 79.55 crore, and PAT was Rs. 23.59 crore, reflecting continuing operations post-demerger.
The company’s CEO highlighted the strategic focus on bio-based specialties and sustainable chemicals post-demerger, emphasizing efforts to enhance operational efficiencies and sustainable growth.
Highlights
- Q2 FY27 standalone revenue at Rs. 358.18 crore, EBITDA at Rs. 39.34 crore, PAT at Rs. 11.24 crore
- Demerger effective April 1, 2026, separated Spirits & Biofuel and Biopharma undertakings into new listed entities
- Half year revenue for H1 FY27 reported at Rs. 712.82 crore with EBITDA of Rs. 79.55 crore
- Q2 FY26 and H1 FY26 figures include demerged units and are not comparable
- Demerger approved by NCLT Allahabad Bench on July 17, 2026, and became effective September 1, 2026
Key Data Snapshot
What happened
- India Glycols Limited reported standalone unaudited financial results for Q2 FY27 following the demerger of its Spirits & Biofuel and Biopharma undertakings.
- The demerger separated these units into two separately listed companies: IGL Spirits Limited and Ennature Bio Pharma Limited.
- Results presented reflect continuing operations focused on bio-based specialty materials, sustainable and performance chemicals, and gases.
Key details
- Q2 FY27 revenue from continuing operations was Rs. 358.18 crore with EBITDA of Rs. 39.34 crore and PAT of Rs. 11.24 crore.
- Comparative Q2 FY26 and H1 FY26 results include the demerged undertakings, making direct comparisons not meaningful.
- The demerger was approved by the National Company Law Tribunal, Allahabad Bench, on July 17, 2026, and became effective September 1, 2026, with an appointed date of April 1, 2026.
Strategic context
- Post-demerger, India Glycols focuses on bio-based specialty materials and sustainable chemistry sectors.
- The company aims to strengthen operational efficiencies and expand business opportunities in bio-based chemicals to create sustainable long-term value.
Highlights
- Q2 FY27 standalone revenue at Rs. 358.18 crore, EBITDA at Rs. 39.34 crore, PAT at Rs. 11.24 crore
- Demerger effective April 1, 2026, separated Spirits & Biofuel and Biopharma undertakings into new listed entities
- Half year revenue for H1 FY27 reported at Rs. 712.82 crore with EBITDA of Rs. 79.55 crore
- Q2 FY26 and H1 FY26 figures include demerged units and are not comparable
- Demerger approved by NCLT Allahabad Bench on July 17, 2026, and became effective September 1, 2026
Disclosures
- SEBI Listing Obligations and Disclosure Requirements Regulations, 2015
- Order of National Company Law Tribunal dated July 17, 2026
More News on General / Other
View allLatest corporate announcements and market updates in General / Other.
State Bank of India Engages with Global Institutional Investors in Singapore Hosted by Bank of America
State Bank of India conducted a meeting with major global institutional investors in Singapore on 17th November 2026, hosted by Bank of America, where only publicly available information was discussed.
Read Full StoryArtemis Medicare Services Limited Opens Special Window for Transfer and Dematerialisation of Physical Securities
Artemis Medicare Services Limited has announced the opening of a Special Window for the transfer and dematerialisation of physical securities through a public notice published on November 17, 2026. This facility allows shareholders to convert their physical share certificates to electronic format within the specified period.
Read Full StoryIGL Spirits Limited Posts Rs 4,837 Crore Revenue with 14.3% Growth in H1 FY27 Following Demerger
IGL Spirits Limited announced its unaudited financial results for Q2 and H1 FY27, posting a 14.3% year-over-year increase in revenue to Rs 4,837.30 crore and a Profit After Tax of Rs 120.79 crore. These are the company's first comparative results following the April 1, 2026 demerger of its spirits and biofuel business from India Glycols Limited.
Read Full Story